Gastric Cancer Diagnostics Market to Garner USD 1,950.82 Million by 2030

PRESS RELEASE
Published July 24, 2023

Gastric Cancer Diagnostics MarketGlobal Gastric Cancer Diagnostics Market research report estimates potential market for new product, consumer’s reaction for particular product, general market tendencies, different types of customers, and intensity of marketing problem. The market report has been generated by keeping in mind all the vital aspects of the market research that simply brings market landscape into focus. By examining competitor analysis, Healthcare industry can get fluency of the strategies of key players in the market that includes new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions. An all-inclusive Global Gastric Cancer Diagnostics Market report displays CAGR value fluctuation during the forecast period of 2023-2030 for the market.

The increase in the global geriatric population is driving the growth of the gastric cancer diagnostics industry. The prevalence of gastrointestinal tumors and lymphomas has also fueled the demand for gastric cancer diagnostics. The key market constraint is the need to lower the high prices associated with cancer diagnostic testing so that even developing countries may benefit from it.

Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gastric-cancer-diagnostics-market&Shri

Data Bridge Market Research analyzes that the global gastric cancer diagnostics market is expected to reach a value of USD 1,950.82 million by 2030, at a CAGR of 8.% during the forecast period. Reagents and consumables account for the largest product type segment in the market due to rising demand for kits and reagents, and increasing health expenditures have accelerated the demand for smart medical devices.

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide, ranking among the top three most common cancers in 19 countries, Bhutan, Kyrgyzstan, Cape Verde, and Tajikistan are the 4 most affected countries. Gastric cancer is responsible for about one in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed worldwide.

Rise in alcohol consumption and surge in smoking is expected to drive the market’s growth

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone, representing a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

The above instances show the relation between smoking and alcohol consumption as a risk factor for gastric cancer. Thus, the rise in alcohol consumption and surge in smoking is expected to drive the global gastric cancer market growth.

Major Players

Some of the major companies providing global gastric cancer diagnostics in the global gastric cancer diagnostics market are BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Teco Diagnostics., Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others.

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the global gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the global gastric cancer market growth.

Recent Developments

  • In October 2022, General Electric Company collaborated with several research institutes such as the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics
  • In March 2020, Thermo Fisher Scientific Inc. announced that it would be acquiring QIAGEN, a Netherland-based molecular diagnostics and healthcare company. This acquisition by the company will increase its product portfolio in the market, leading to increased revenue in future

To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@  https://www.databridgemarketresearch.com/reports/global-gastric-cancer-diagnostics-market?Shri 

Gastric Cancer Diagnostics Market Scope

PRODUCT TYPE

  • Instruments
  • Reagents & Consumables
  • Services

On the basis of product type, the market is segmented into instruments, reagents & consumables, and services.

DIAGNOSTIC TYPE

  • Confirmatory Test
  • Gastric Cancer Screening Tests/Physical Exam

On the basis of diagnostics type, the market is segmented into gastric cancer screening tests/physical exam and confirmatory tests.

AGE GROUP

  • Adult
  • Pediatric
  • Geriatrics

On the basis of age group, the market is segmented into adult, pediatric, and geriatrics.

TYPE

  • Intestinal Or Diffuse Adenocarcinoma
  • Carcinoid Tumor
  • Gastrointestinal Stromal Tumor (GIST)
  • Gastric Lymphoma
  • Others

On the basis of type, the market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, gastrointestinal stromal tumor (GIST), gastric lymphoma, and others.

STAGE

  • Stage 0
  • Stage I
  • Stage II
  • Stage III

On the basis of stage, the market is segmented into stage 0, stage I, stage II, and stage III.

GENDER

  • Male
  • Female

On the basis of gender, the market is segmented into male and female.

SAMPLE TYPE

  • Blood
  • Tissue
  • Urine
  • Stool

On the basis of sample type, the market is segmented into blood, tissue, urine, and stool.

END USER

  • Diagnostic Laboratories
  • Hospitals
  • Cancer Research Institutes
  • Oncology Specialty Clinics
  • Others

On the basis of end users, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others.

DISTRIBUTION CHANNEL

  • Direct Tenders
  • Retail Sales

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the this research report
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Top Key Topics Covered:

  1. Strategic Imperatives
  • Factors Creating Pressure on Growth
  • The Strategic Imperative
  • Growth Opportunities Fuel the Growth Pipeline Engine
  • Research Methodology
  1. Scope and Segmentation
  • Research Context and Scope of Analysis
  • Segmentation
  • Other Techniques for This Research Report Management
  1. Growth Opportunity Analysis
  • Growth Drivers
  • Growth Restraints
  1. Introduction
  • The Impact of the COVID-19 Pandemic and Post
  • Future Growth
  1. Innovation Ecosystem

Continued…

TOC:

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL’S MODEL

4.2 PORTER’S 5 FORCES

4.3 EPIDEMIOLOGY

4.4 BRAND ANALYSIS

4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET

4.6 INDUSTRY INSIGHTS:

5 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY

5.1 NORTH AMERICA

5.1.1 REGULATORY SCENARIO IN THE U.S

5.2 EUROPEAN UNION (EU)-

5.3 ASIA-PACIFIC

5.3.1 REGULATORY SCENARIO IN AUSTRALIA-

5.3.2 REGULATORY SCENARIO IN JAPAN

5.3.3 REGULATORY SCENARIO IN CHINA

5.3.4 REGULATORY SCENARIO IN SINGAPORE-

6 MARKET OVERVIEW

7 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

8 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

9 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP

10 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE

Continued…

Browse Detailed Summary of Research Report with TOC:  https://www.databridgemarketresearch.com/toc/?dbmr=global-gastric-cancer-diagnostics-market&Shri

Some of the Most Important Questions Scrutinized in the Business Intelligence Report:

  • What are the key growth parameters for this global market during the forecast period?
  • Which key players are expected to hold the largest market share over the forecast period?
  • Who are the leading vendors and manufacturers in this market?
  • What are the key strategies adopted by leading players in the market for business development and geographical expansion?
  • Which end-use industries can trigger high demand in the market over the forecast period?
  • What are the key segments in this market?
  • Which regional player will have anticipated leading the global market in terms of size?
  • What is the impact of the novel coronavirus pandemic?
  • Which obstacles must new players overcome in order to occupy a major position?

Top DBMR Healthcare Reports:        

https://www.databridgemarketresearch.com/reports/global-cardasil-treatment-market?Shri

https://www.databridgemarketresearch.com/reports/global-aestheticcosmetic-lasers-market?Shri

https://www.databridgemarketresearch.com/reports/global-pharmaceutical-laboratory-information-management-systems-market?Shri

https://www.databridgemarketresearch.com/reports/global-protein-crystallization-crystallography-market?Shri

https://www.databridgemarketresearch.com/reports/india-analytical-chromatography-in-pharma-quality-control-market?Shri

https://www.databridgemarketresearch.com/reports/global-yeast-infection-market?Shri

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com

CDN Newswire